254 Appendices REFERENTIES 1. Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. The Lancet Neurology. 2022;21:72634. 2. Ossenkoppele R, Prins ND, Van Berckel BN. Amyloid imaging in clinical trials. Alzheimer’s research & therapy. 2013;5:1-3. 3. van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. Journal of Nuclear Medicine. 2013;54:1570-6. 4. Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, et al. Optimized dual-time-window protocols for quantitative [18F] flutemetamol and [18F] florbetaben PET studies. EJNMMI research. 2019;9:1-14. 5. Leuzy A, Binette AP, Vogel JW, Klein G, Borroni E, Tonietto M, et al. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA neurology. 2023. 6. Wolters EE, Golla SS, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, et al. A novel partial volume correction method for accurate quantification of [18 F] flortaucipir in the hippocampus. EJNMMI research. 2018;8:1-5. 7. Wolters EE, Ossenkoppele R, Golla SS, Verfaillie SC, Timmers T, Visser D, et al. Hippocampal [18F] flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. NeuroImage: Clinical. 2020;25:102113. 8. Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143:2818-30. 9. Lowe VJ, Lundt ES, Albertson SM, Min H-K, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimer’s & Dementia. 2019. 10. Ahmadi K, Pereira JB, Berron D, Vogel J, Ingala S, Strandberg OT, et al. Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease. Journal of Cerebral Blood Flow & Metabolism. 2022:0271678X221141139. 11. Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87:375-83. 12. Gordon BA, McCullough A, Mishra S, Blazey TM, Su Y, Christensen J, et al. Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2018;10:245-52. 13. La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Science translational medicine. 2020;12:eaau5732. 14. Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SC, Visser D, Golla SS, et al. Associations between quantitative [18F] flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum. Alzheimer’s research & therapy. 2019;11:1-12.
RkJQdWJsaXNoZXIy MjY0ODMw